R1	multi Arg1:T2 Arg2:T3	
R2	Has_index Arg1:T4 Arg2:T5	
R3	Has_temporal Arg1:T2 Arg2:T4	
R4	AND Arg1:T1 Arg2:T2	
*	OR T7 T9 T8
R5	Has_temporal Arg1:T7 Arg2:T6	
R6	Has_qualifier Arg1:T12 Arg2:T13	
*	OR T11 T14
R7	Has_qualifier Arg1:T12 Arg2:T11	
R8	Has_index Arg1:T16 Arg2:T17	
R9	Has_temporal Arg1:T12 Arg2:T16	
R10	Has_mood Arg1:T19 Arg2:T18	
R11	Has_temporal Arg1:T19 Arg2:T20	
R12	Has_index Arg1:T20 Arg2:T21	
*	OR T12 T19
R13	Has_index Arg1:T26 Arg2:T27	
R14	Has_temporal Arg1:T25 Arg2:T26	
R15	Has_multiplier Arg1:T25 Arg2:T24	
R16	Has_temporal Arg1:T22 Arg2:T23	
*	OR T22 T25
R17	Subsumes Arg1:T28 Arg2:T29	
R18	Has_qualifier Arg1:T31 Arg2:T32	
*	OR T30 T31
R19	Has_multiplier Arg1:T30 Arg2:T28	
R20	multi Arg1:T35 Arg2:T36	
R21	Has_index Arg1:T34 Arg2:T35	
R22	Has_value Arg1:T38 Arg2:T39	
R23	Has_qualifier Arg1:T39 Arg2:T41	
R24	Has_multiplier Arg1:T37 Arg2:T38	
R25	Has_negation Arg1:T37 Arg2:T40	
R26	Has_temporal Arg1:T30 Arg2:T34	
R27	AND Arg1:T30 Arg2:T37	
*	OR T45 T46
R28	Has_qualifier Arg1:T44 Arg2:T43	
R29	Has_qualifier Arg1:T44 Arg2:T45	
T1	Observation 0 14	Primary groups
T2	Procedure 16 49	Vaccination against typhoid fever
T3	Condition 36 49	typhoid fever
T4	Temporal 50 78	within 5 years before dosing
T5	Reference_point 72 78	dosing
T6	Temporal 81 88	History
T7	Condition 92 114	clinical typhoid fever
T8	Condition 116 138;144 149	clinical paratyphoid A fever
T9	Condition 116 136;142 149	clinical paratyphoid B fever
T12	Procedure 152 169;180 187	Immunization with vaccine
T13	Qualifier 170 179	any other
T11	Qualifier 189 193	oral
T14	Qualifier 197 207	parenteral
T16	Temporal 209 244	within 4 weeks prior to study start
T17	Reference_point 233 244	study start
T18	Mood 248 255	planned
T19	Procedure 256 267	vaccination
T20	Temporal 268 284	during the study
T21	Reference_point 275 284	the study
T22	Drug 304 315	antibiotics
T23	Temporal 286 293	Current
T24	Multiplier 319 325	end of
T25	Procedure 326 344	antibiotic therapy
T26	Temporal 345 384	<8 days before first IMP administration
T27	Reference_point 360 384	first IMP administration
T28	Multiplier 386 393;416 430	Chronic administration
T29	Multiplier 395 414	longer than 14 days
T30	Drug 434 452	immunosuppressants
T31	Drug 462 484	immune-modifying drugs
T32	Qualifier 456 461	other
T34	Temporal 485 549	within 6 months before the first dose of investigational vaccine
T35	Reference_point 508 549	the first dose of investigational vaccine
T36	Drug 526 549	investigational vaccine
T37	Drug 551 571	oral corticosteroids
T38	Multiplier 575 582	dosages
T39	Value 586 598	=0.5 mg/kg/d
T40	Negation 630 638	excluded
T41	Qualifier 599 625	prednisolone or equivalent
T42	Non-representable 640 679	inhaled or topical steroids are allowed
T43	Qualifier 698 720	clinically significant
T44	Condition 721 745	gastrointestinal disease
T45	Qualifier 681 686	Acute
T46	Qualifier 690 697	chronic
